Teva’s Armodafinil Study Fails to Meet Primary Endpoint

Armodafinil, a drug from Teva Pharmaceutical Industries Ltd (TEVA), used as a prescription for obstructive sleep apnoea has failed to meet the primary endpoint of a study. In the final stage of the study the drug as an adjunct therapy for major depression associated Bipolar I disorderin adults, did not meet the primary objectives of the study. The treatment was in no way effective in treatment of these conditions.

Read more here:

http://www.euroinvestor.com/news/2013/08/30/tevaaposs-armodafinil-study-fails-to-meet-primary-endpoint/12477642

Somnowell Inventor - Visiting Professor Simon Ash FDS MSc MOrth BDS

Prof. Ash is the inventor of the highly successful SOMNOWELL Chrome device for snoring and sleep apnoea.

The Somnowell Chrome is made to exacting standards in the Somnowell laboratory under the supervision of Visiting Professor Simon Ash. Prof. Ash and his master technicians create each Somnowell Chrome device using their wealth of experience and expertise.

Prof. Ash works at the forefront of his profession. He is a Consultant and Specialist Orthodontist with over 30 years clinical experience, with a special interest in sleep related breathing disorders, TMJD, and bruxism. He currently works in Harley Street London and two private hospitals in London as part of a multi-disciplinary team managing snoring and sleep apnoea, and is Visiting Professor of Orthodontics at the BPP University.